William New

William New

What Is Fair Pricing For Medicines? WHO-Netherlands Forum Aims To Find Out

Public health stakeholders – and just about everyone else – may take notice of a meeting planned for May in the Netherlands, as it could offer the beginning of a new approach to pharmaceutical costs. High drug prices have become a ‘kitchen table’ issue in countries of all economic sizes recently, and the World Health Organization is teaming up with the Dutch government to address it in a new and practical way.

US Business, Government Work To Bring Down ‘Dangerous’ UN Panel Report On Access To Medicines – And Change The Debate In Geneva

Calling it flawed and narrow and seemingly threatened by its contents, the leading United States business group and US government IP specialists are working to limit the impact of a recent United Nations report that made recommendations for the decades-old problem of ensuring affordable medicines reach people when they are under patent in a way that does not threaten innovation. One step in countering the UN report? Change the discourse in Geneva and elsewhere.

Special Report: WHO Board Sets Review Of 10-Year Effort To Boost Medicines Access, Affordability

Once considered a breakthrough in negotiations to address problems of making cutting-edge medical products and research available to poor countries, the decade-old World Health Organization Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA) is now undergoing review, with the WHO Executive Board calling for a report on the initiative and plans for its future next year.

US Chamber International IP Index: US, Europe At Top; India Needs A Push

The United States Chamber of Commerce today released its fifth annual International IP Index, which makes the case for the positive impact of intellectual property on economies. The United States scored highest, followed by top European economies and Japan. And near the bottom was India, despite recent efforts to accept the IP system. Separately, the report assesses international trade rules for IP and argues for nations to negotiate "TRIPS-plus" agreements.